Text Size

Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo & Active Control in Generalized Anxiety Disorder (GOLD)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00329446
First received: May 22, 2006
Last updated: March 24, 2009
Last verified: March 2009
History of Changes
  Purpose

The purpose of this study is to demonstrate that quetiapine SR (SEROQUEL®) is efficacious and safe in the acute treatment of patients with Generalized Anxiety Disorder.

PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.


Condition Intervention Phase
Generalized Anxiety Disorder
 Drug: Quetiapine Fumarate
Drug: Escitalopram oxylate
 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Controlled Study of the Efficacy and Safety of Sustained-Release Quetiapine Fumarate (SEROQUEL®) Compared With Placebo in the Treatment of Generalized Anxiety Disorder

Resource links provided by NLM:

MedlinePlus related topics: Anxiety
U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Change from randomization in the HAM-A total score at Day 57

Secondary Outcome Measures:
  • Change from randomization in CGI-S score at Day 57

Estimated Enrollment: 800
Study Start Date: April 2006
Study Completion Date: September 2007
  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient has a documented clinical diagnosis of Generalized Anxiety Disorder.
  • Be able to understand and comply with the requirements of the study.
  • Able to understand and provide written informed consent

Exclusion Criteria:

  • Patients (female) must not be pregnant or lactating
  • Current or past diagnosis of stroke or transient ischemic attack (TIA).
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00329446

  Hide Study Locations
Locations
United States, Alabama
Research Site
Birmingham, Alabama, United States
United States, Arizona
Research Site
Scottsdale, Arizona, United States
United States, Arkansas
Research Site
Little Rock, Arkansas, United States
United States, California
Research Site
Beverly Hills, California, United States
Research Site
Burbank, California, United States
Research Site
La Mesa, California, United States
Research Site
Orange, California, United States
Research Site
Pasadena, California, United States
Research Site
San Diego, California, United States
Research Site
Sherman Oaks, California, United States
Research Site
Upland, California, United States
Research Site
Wildomar, California, United States
United States, Connecticut
Research Site
New Britain, Connecticut, United States
United States, District of Columbia
Research Site
Washington, District of Columbia, United States
United States, Florida
Research Site
Boca Raton, Florida, United States
Research Site
Bradenton, Florida, United States
Research Site
Deland, Florida, United States
Research Site
Fort Lauderdale, Florida, United States
Research Site
Ft Myers, Florida, United States
Research Site
Jacksonville, Florida, United States
Research Site
Maitland, Florida, United States
Research Site
Miami, Florida, United States
Research Site
Orlando, Florida, United States
Research Site
Tampa, Florida, United States
Research Site
West Palm Beach, Florida, United States
United States, Illinois
Research Site
Edwardsville, Illinois, United States
United States, Indiana
Research Site
Merrillville, Indiana, United States
Research Site
Terre Haute, Indiana, United States
United States, Kansas
Research Site
Newton, Kansas, United States
Research Site
Prairie Village, Kansas, United States
United States, Kentucky
Research Site
Owensboro, Kentucky, United States
United States, Louisiana
Research Site
Lake Charles, Louisiana, United States
United States, Maryland
Research Site
Baltimore, Maryland, United States
United States, Massachusetts
Research Site
Boston, Massachusetts, United States
Research Site
Haverhill, Massachusetts, United States
United States, Michigan
Research Site
Okemos, Michigan, United States
United States, Minnesota
Research Site
St. Paul, Minnesota, United States
United States, Missouri
Research Site
St. Louis, Missouri, United States
United States, New Jersey
Research Site
Kenilworth, New Jersey, United States
Research Site
Princeton, New Jersey, United States
Research Site
Toms River, New Jersey, United States
United States, New Mexico
Research Site
Albuquerque, New Mexico, United States
United States, New York
Research Site
New York City, New York, United States
United States, North Carolina
Research Site
Chapel Hill, North Carolina, United States
United States, Ohio
Research Site
Cleveland, Ohio, United States
Research Site
Dayton, Ohio, United States
Research Site
Toledo, Ohio, United States
United States, Oklahoma
Research Site
Oklahoma City, Oklahoma, United States
United States, Oregon
Research Site
Eugene, Oregon, United States
Research Site
Salem, Oregon, United States
United States, Pennsylvania
Research Site
Allentown, Pennsylvania, United States
Research Site
Philadelphia, Pennsylvania, United States
United States, South Carolina
Research Site
Columbia, South Carolina, United States
United States, Tennessee
Research Site
Memphis, Tennessee, United States
Research Site
Nashville, Tennessee, United States
United States, Texas
Research Site
Dallas, Texas, United States
Research Site
Houston, Texas, United States
Research Site
San Antonio, Texas, United States
United States, Utah
Research Site
Salt Lake City, Utah, United States
United States, Virginia
Research Site
Richmond, Virginia, United States
United States, Washington
Research Site
Kirkland, Washington, United States
Research Site
Spokane, Washington, United States
United States, West Virginia
Research Site
Morgantown, West Virginia, United States
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Anders Neijber, MD AstraZeneca
  More Information

No publications provided by AstraZeneca

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

ClinicalTrials.gov Identifier: NCT00329446     History of Changes
Other Study ID Numbers: D1448C00010, GOLD
Study First Received: May 22, 2006
Last Updated: March 24, 2009
Health Authority: United States: Food and Drug Administration

Keywords provided by AstraZeneca:
GAD
anxiety

Additional relevant MeSH terms:
Anxiety Disorders
Mental Disorders
Dexetimide
Citalopram
Quetiapine
Antiparkinson Agents
Anti-Dyskinesia Agents
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Parasympatholytics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
 Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Serotonin Agents
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants

ClinicalTrials.gov processed this record on May 16, 2013